Case

MROE

undefined

Case Studies -1

Case Studies -1

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

MROE

undefined

Case Studies-2

Case Studies-2

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

MROE

undefined

Case Studies-3

Case Studies-3

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

MROE

undefined

Case Studies-4

Case Studies-4

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

MROE

undefined

Case Studies-5

Case Studies-5

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

MROE

undefined

Case Studies-6

Case Studies-6

Our API base meets the modern generic drug R&D and API production requirements of FDA and CGMP, and is an export-oriented high-end pharmaceutical raw material production base based on EHS requirements of ISO and OSHA and cGMP standards of FDA and EU, and will soon be inspected by FDA and EU cGMP.

< 1 >

R&D strategy

With the motivation of providing drugs for major diseases, taking into account special varieties, with pharmacoepidemiology and network pharmacology as the theoretical support, and with strict project management and whole process evaluation as the main means, we fully integrate and utilize excellent resources at home and abroad, cultivate and develop a drug R&D team with excellent technology and high efficiency, and build a high-level drug R&D platform with Qirui's characteristics.

In the field of generic drugs, we will achieve "superiority of others and superiority of others";

Focus on Me-too and Me-better drug development in the field of innovative drugs;

Gradually develop First-in-class drug development;

We do not make products that are not "difficult".

济南弘祥机床刀具制造有限公司
全部
  • 全部
  • 产品管理
  • 新闻资讯
  • 介绍内容
  • 企业网点
  • 常见问题
  • 企业视频
  • 企业图册
Search